Therapeutic up- or downregulation of EPHA2, EPHA3, EPHA5, and EPHA7, not only directly influence complex molecular pathways related to LC cell survival and progression, but also enhance the therapeutic efficacy of well-established treatment regimens (chemotherapy/radiotherapy/targeted therapy) for advanced LC. The gene discussed is EPHA2; the disease is laryngotracheoesophageal cleft.